The latest findings provide reassurance for nephrologists who may be hesitant to prescribe these types of medications.

Finerenone prevented new-onset atrial fibrillation or flutter in patients with chronic kidney disease and type 2 diabetes or ...

Diuretic use does not affect safety and efficacy outcomes in patients with type 2 diabetes and chronic kidney disease receiving finerenone.

25) explored the effects of finerenone (Kerendia; Bayer HealthCare) on clinical outcomes and bilirubin levels in patients with heart failure with preserved ejection fraction. Although recent ...

Bayer's big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in diabetics has paid off with an FDA approval, although it could face stiff competition ...

BLA accepted for Priority Review Finerenone (Bayer) Nonsteroidal mineralocorticoid receptor antagonist Treatment of adult patients with heart failure with mildly reduced or preserved ejection ...

our findings point to finerenone as a new second pillar in HFmrEF/HFpEF." Bayer is running an open-label study – CONFIRMATION-HF – testing Kerendia with Jardiance in patients hospitalised or ...

Bayer AG BAYRY recently announced that the FDA had accepted its supplemental new drug application (sNDA) seeking approval for Kerendia (finerenone) to treat a new indication.The sNDA seeks ...

The approval of KERENDIA (finerenone), a non-steroidal mineralocorticoid receptor antagonist, has further expanded treatment options by addressing inflammation and fibrosis pathways in diabetic ...

BLA accepted for Priority Review Finerenone (Bayer) Nonsteroidal mineralocorticoid receptor antagonist Treatment of adult patients with heart failure with mildly reduced or preserved ejection fraction ...